VulnerabilityModified
CVE-2021-43935
The impacted products, when configured to use SSO, are affected by an improper authentication vulnerability.
CRITICAL 9.8EPSS 1.08%
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (1.08%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
The impacted products, when configured to use SSO, are affected by an improper authentication vulnerability. This vulnerability allows the application to accept manual entry of any active directory (AD) account provisioned in the application without supplying a password, resulting in access to the application as the supplied AD account, with all associated privileges.
- CVSS 3.1
- 9.8 CRITICALCVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
- EPSS
- 1.08% probability · 63th percentile
- CISA KEV
- Not listed
- Weakness
- CWE-288, CWE-287
- Affected
- baxter/welch allyn connex cardio · baxter/welch allyn diagnostic cardiology suite · baxter/welch allyn rscribe resting ecg system · baxter/welch allyn vision express holter analysis system · baxter/welch allyn hscribe holter analysis system firmware · baxter/welch allyn q-stress cardiac stress testing system firmware · baxter/welch allyn xscribe cardiac stress testing system firmware
- Source
- ics-cert@hq.dhs.gov
References
- https://www.cisa.gov/uscert/ics/advisories/icsma-21-343-01Mitigation, Third Party Advisory, US Government Resource
- https://www.cisa.gov/uscert/ics/advisories/icsma-21-343-01Mitigation, Third Party Advisory, US Government Resource
Source: NVD record, EPSS from FIRST.org, KEV from CISA. Refreshed daily.